Clinical Trial Results TV
November 15, 2011: Dr. Stephen Nicholls and Dr. Dylan Steen discuss: Lipid-modulating effects of evacetrapib, a novel CETP inhibitor, admin
Lipid-modulating effects of evacetrapib, a novel CETP inhibitor, administered as
monotherapy or in combination with the most commonly used statins

Research support: AstraZeneca, Anthera, Eli Lilly, Novartis, Resverlogix, Roche and
LipoScience

Consulting and honoraria: AstraZeneca, Eli Lilly, Anthera, Omthera, Merck, Takeda,
Resverlogix, Sanofi-Aventis, CSL Behring, Esperion, Boehringer Ingelheim

The study was sponsored by Eli Lilly

[ Download video ]


Video Statistics
4.83 out of 5

1 Star 2 Star 3 Star 4 Star 5 Star

click a star to vote
This submission has received 6 total votes.

These statistics are updated nightly. The last update ran on
05-29-2017 EST at 1 am.

Additional Files
Filename File Description Action
No additional files available

Comments [ login to comment ]
No comments have been submitted